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years of study which span its introduction to use in 2005. The
activity by MIC90 was also consistent in each study period,
regardless of the PL and SS of the tested isolates. Contin-
ued surveillance is warranted both to support the further
clinical development of TIG and to detect any emerging
resistance among target pathogens for indications which TIG
is currently approved (cSSSI and cIAI).
doi:10.1016/j.ijid.2008.05.1065
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Dalbavancin Tested Against Staphylococcus spp. and
Streptococcus spp. Isolates collected from Five European
Counties: Comprehensive DECIDE Program Results (2007)
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JMI Laboratories, North Liberty, IA, USA
Background: Dalbavancin is a novel lipoglycopeptide with
an extended half-life and intended for treating complicated
skin and skin structure infections caused by S. aureus (SA)
and -haemolytic streptococci (BHS). The DECIDE Program
was initiated to assess the activity of dalbavancin compared
to vancomycin or teicoplanin (Italy only) against recent
(2007) clinical isolates from across Europe (EU).
Methods: Eighteen sites in France, Germany, Spain, Italy
and UK utilized standardized, reference-quality agar diffu-
sion methods including Etest and CLSI (M2-A9) disk diffusion
(DD) tests with concurrent QC (CLSI M100-S18, 2008). 1,127
strains were tested against dalbavancin and comparison
glycopeptides by Etest. DD was used for linezolid, cefox-
itin, levoﬂoxacin, gentamicin, tetracycline, erythromycin,
clindamycin (plus D-test), penicillin and ceftriaxone. Dalba-
vancin susceptibility was deﬁned at ≤0.25mg/L.
Results: Dalbavancin exhibited potent activity
against the SA and coagulase-negative staphylococci
(CoNS; MIC50/90, 0.064/0.19mg/L), and BHS (MIC50/90,
≤0.016/0.047mg/L). Overall, vancomycin and teicoplanin
were ≥eight-fold less potent. Italy had higher dalbavancin
MIC values (two-fold) for SA and the highest MRSA rate
(44%) compared to other nations (8—36%). Dalbavancin
MIC90 values were slightly higher for group B (0.047mg/L)
compared to group A (0.032mg/L) streptococci. Nearly 4%
of BHS isolates were levoﬂoxacin-non-susceptible. Among
SA, resistance rates were: erythromycin (29%), clindamycin
(13%), gentamicin (10%), and levoﬂoxacin (29%) with
higher resistance rates among MRSA. Inducible clindamycin
resistance was high among SA (72%) and CoNS (48%) and
less among BHS (25%). Rare strains had non-susceptible MIC
values for linezolid (0.3%) and vancomycin (0.1%)
Conclusions: Dalbavancin demonstrated pronounced
activity (MIC, ≤0.25mg/L) against staphylococci and BHS
from European countries. Due to dalbavancin’s high molec-
ular weight, like other peptides, care must be taken
when interpreting Etest-generated MICs (false resistance).
Dalbavancin provides coverage of contemporary Gram-
positive pathogens, including resistant isolates recovered
from patients in Europe, conﬁrming earlier USA reports.
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Background: Ertapenem is a relatively new carbapenem
with broad activity. There are however limited studies
regarding its efﬁcacy in bacteremic patients. We evalu-
ated the in-vitro activity of Ertapenem against blood culture
isolates (community onset and nosocomial) at a tertiary hos-
pital.
Methods: Bacteria isolated from blood cultures from
hospitalized patients admitted to the National University
Hospital, Singapore (Dec 2003—May 2004) were identiﬁed
using the Vitek instrument (bioMerieux, NC) and Microbact
12A and 12B (Oxoid Australia). Gram-stain, catalase, coag-
ulase (Pastorex Staph Plus, Bio-Rad, CA) and PYR disk
testing were done for Staphylococcusand Streptococcus spp.
Ertapenem susceptibilities were determined using the Kirby-
Bauer disk method on cation-adjusted Mueller-Hinton plates
according to the CLSI performance standards. Burkholderia
pseudomallei (B. pseudomallei) isolates were further tested
using the E-test (AB Biodisk, Sweden).
Results: 333 blood stream isolates were studied,
including 157 Enterobacteraciae (73 Extended spectrum
beta-lactamase (ESBL) positive) and 29 isolates of B. pseudo-
mallei. All 157 Enterobacteraciae isolates were Ertapenem
susceptible. 26 B. pseudomallei strains were susceptible
and 3 strains intermediate to Ertapenem by disk testing,
but the E-test showed that only 5 of the 29 strains were
susceptible (MIC≤2mcg/ml). Of the non-fermenting gram-
negatives, 26 of 64 isolates were susceptible (including 4/6
B. cepacia, 8/26 A. baumanii and 3/10 P. aeruginosa iso-
lates). All isolates of S. maltophila (9/9) were resistant. Of
the gram-positives, 2/2 L. monocytogenes and all S. viridans
(5/5), beta-hemolytic Streptococci (11/11), S. pneumoniae
(6/6), methicillin susceptible S. aureus (32/32) were sus-
ceptible. All 12 strains of penicillin susceptible E. faecalis
were non-susceptible to Ertapenem, whilst 9 of the 10 B.
fragilis strains tested were
Conclusions: Ertapenem demonstrates excellent activity
against enterobacteraciae including ESBL producing strains
at our institution but is lacking against A. baumannii, P.
aeruginosa, S. maltophilia and E. faecalis. It also has poor
activity against B. pseudomallei and cannot be recom-
mended as therapy for melioidosis.
doi:10.1016/j.ijid.2008.05.1067
